Trial reportBritish journal of cancer2007
A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma.
Trial report in British journal of cancer, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Trial
- Two homologous sequences of Grp78 and HSP70 represent tumor antigens shared with streptococcal superantigens in eliciting an antitumor immune response: an immunoinformatic investigation.Frontiers in immunology · 2025Article
- Enhancing immune responses of ESC-based TAA cancer vaccines with a novel OMV delivery system.Journal of nanobiotechnology · 2024Article
- A T cell receptor β chain-directed antibody fusion molecule activates and expands subsets of T cells to promote antitumor activity.Science translational medicine · 2023Article
- Novel SPEA Superantigen Peptide Agonists and Peptide Agonist-TGFαL3 Conjugate. In Vitro Study of Their Growth-Inhibitory Effects for Targeted Cancer Immunotherapy.International journal of molecular sciences · 2023Article
- Immunosuppressive Signaling Pathways as Targeted Cancer Therapies.Biomedicines · 2022Review
- Design of split superantigen fusion proteins for cancer immunotherapy.The Journal of biological chemistry · 2019Article
- 5T4 oncofoetal antigen: an attractive target for immune intervention in cancer.Cancer immunology, immunotherapy : CII · 2017Review
- Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential.Therapeutic advances in medical oncology · 2016Review
- Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin.Current oncology reports · 2014Review
- Article
- Target expression of Staphylococcus enterotoxin A from an oncolytic adenovirus suppresses mouse bladder tumor growth and recruits CD3+ T cell.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Article
- Article
- Article
- Regulation of autologous immunity to the mouse 5T4 oncofoetal antigen: implications for immunotherapy.Cancer immunology, immunotherapy : CII · 2012Article
- Human TGFalpha-derived peptide TGFalphaL3 fused with superantigen for immunotherapy of EGFR-expressing tumours.BMC biotechnology · 2010Article
- Update on vaccine development for renal cell cancer.Open access journal of urology · 2010Review
- Perspectives in drug development for metastatic renal cell cancer.Targeted oncology · 2010Review
- Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2009Article
- CD4+ T-cell recognition of human 5T4 oncofoetal antigen: implications for initial depletion of CD25+ T cells.Cancer immunology, immunotherapy : CII · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In a phase II study, 43 renal cell carcinoma patients were treated with individualised doses of ABR-214936; a fusion of a Fab recognising the antigen 5T4, and Staphylococcal enterotoxin A. Drug was given intravenously on 4 consecutive days, treatment was repeated 1 month later. Treatment was associated with moderate fever and nausea, but well tolerated. Of 40 evaluable patients, 28 had disease control at 2 months, and at 4 months, one patient showed partial response (PR) and 16 patients stable disease. Median survival, with minimum follow-up of 26 months was 19.7 months with 13 patients alive to date. Stratification by the Motzer's prognostic criteria highlights prolonged survival compared to published expectation. Patients receiving higher drug exposure had greater disease control and lived almost twice as long as expected, whereas the low-exposure patients survived as expected. Sustained interleukin-2 (IL-2) production after a repeated injection appears to be a biomarker for clinical effect, as the induced-IL-2 level on the day 2 of treatment correlated with survival. The high degree of disease control and the prolonged survival suggest that this treatment can be effective. These findings will be used in the trial design for the next generation of drug, with reduced antigenicity and toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.